CXCL1 and bone cancer: In summary, the current findings identify an unrecognized pharmacological property of RvD2 in preventing and attenuating chronic neuropathic pain and bone cancer pain by spinal inhibition of IL-17 secretion, CXCL1 release and astrocyte activation.